

# TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market

- Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction
- Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance
- One of many distribution agreements in pipeline for Europe as part of TempraMed's defined, strategic expansion strategy

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - **TempraMed Technologies Ltd.** (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), an innovator in smart temperature-controlled medical devices, is pleased to announce that it has entered into a definitive exclusive distribution agreement with Dolfin Sağlık Ürünleri ("Dolfin Sağlık") to market and sell TempraMed's "VIVI" line of medication temperature-stabilizing products throughout Turkey.

Founded in 2002, Dolfin Sağlık is one of Turkey's most recognized and trusted medical device and supplies companies. The firm serves a wide range of healthcare stakeholders including leading public and private hospitals, emergency/ambulance services, educational institutions, provincial health directorates,. Dolfin Sağlık has established a national presence built on reliability, customer service, and technological innovation, while delivering premium medical solutions across the country.

Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance. The Turkish diabetes market represents a significant commercialization opportunity for TempraMed. Approximately 10 million people in Turkey live with diabetes, with an estimated over 1 million patients using insulin<sup>[1]</sup> and additional number GLP-1 users. A large proportion of these patients depend on temperature-sensitive medications that are highly vulnerable to degradation when exposed to heat or cold daily. TempraMed's VIVI products eliminate the need for conventional cooling, protecting critical medications, like insulin, Epi Pens, biologics, fertility medications, GLP-1 therapies, for example, from extreme temperatures through patented smart insulation technology.

*"As one of Turkey's leading medical distributors, with a 20-year track record of excellence in clinical product procurement, service, and delivery, Dolfin's deep relationships across emergency care, hospitals, educational institutions, and individual patient networks make them a powerful commercialization partner. This agreement accelerates our expansion into a large and fast-growing diabetes market, helping ensure that insulin users across Turkey can safely protect their medication in real-world conditions," said Ron Nagar, CEO of TempraMed. "This agreement is another key driver in our strategic expansion plans, as we continue to roll out our distribution coverage across Europe and beyond. We continue to execute on our defined strategy, and over the next 12 months we plan to continue: (1) expanding our product offering globally, (2) adding new products and verticals to our portfolio, and (3) leveraging our direct-to-consumer business (B2C) to drive new institutional and B2B partnership to efficiently scale the business."*

*"We have been dedicated to bringing innovative medical solutions to Turkey for over two decades, and VIVI is unlike anything currently available in our market," said Tolga ORUÇOĞLU General Manager of Dolfin Sağlık. "Insulin and other temperature-regulated medication users need reliable medication protection in extreme environments, during travel, and in everyday scenarios where temperature fluctuations are unavoidable. TempraMed's product portfolio provides a validated*

*solution that delivers confidence, efficacy, and safety without requiring cooling or daily maintenance. We look forward to a long-term partnership with TempraMed and to introducing its products to the Turkish healthcare ecosystem."*

This agreement reinforces TempraMed's global commercialization strategy to transition from online direct-to-consumer channels toward retail pharmacy networks, regional distributors, insurers, and institutional healthcare partners. The partnership with Dolfin Sağlık is expected to accelerate market penetration among insulin-dependent and GLP-1 using patients and providers, including hospitals, family medicine clinics, diabetes educators, and national purchasing entities.

With more than eight global patents, TempraMed continues to scale commercial access to its proprietary technology-a compact, maintenance-free solution that protects temperature-sensitive injectable medications for extended periods, eliminating the risks of degradation, spoilage, or reduced therapeutic impact.

## **About Dolfin Sağlık Ürünleri**

Founded in 2002, Dolfin Sağlık Ürünleri has become one of Turkey's leading companies in medical devices and healthcare supplies. The company provides ambulance and emergency equipment, hospital fixtures, rescue tools, medical devices, and high-quality consumables. Dolfin Sağlık serves major healthcare institutions, including university hospitals, military hospitals, municipalities, private hospitals, and family medicine clinics, as well as the education and consumer sectors. Dolfin Sağlık's success is rooted in innovative design, customer-focused product development, efficient sales and after-sales service, and rapid nationwide distribution. Find out more here: [www.myvivi.com.tr](http://www.myvivi.com.tr).

Instagram: <https://www.instagram.com/dolfinsagliktr/?igsh=MW4zaHN0d3F2dTh0ZA%3D>

Facebook: [https://www.facebook.com/profile.php?id=61583643358336&name=xhp\\_nt\\_fb\\_action\\_open\\_user](https://www.facebook.com/profile.php?id=61583643358336&name=xhp_nt_fb_action_open_user)

## **About TempraMed Technologies Ltd.**

TempraMed is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation hassle-free devices that work 24/7 for years without charging or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.

**Investors interested learning more about TempraMed are encouraged to contact the Company at:**

[ir@tempramed.com](mailto:ir@tempramed.com)  
[www.tempramed.com](http://www.tempramed.com)

Ron Nagar  
*Chief Executive Officer*  
TempraMed Technologies Ltd.

## **Investor Contacts:**

Julia Becker  
*Vice President, Capital Markets*  
T: +1 (604) 785-0850  
E: [julia@tempramed.com](mailto:julia@tempramed.com)

## **Forward-Looking Statements**

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: the role Dolfin will play in bringing TempraMed's solutions to the Turkish market; expectations regarding market demand for TempraMed's products in Turkey; the Company's global expansion program covering Europe, the Middle East, North America, and Asia; the Company's focus on embedding TempraMed's technology within retail and clinical ecosystems; and expectations that the partnership will make temperature-safe medication storage the global standard, improving outcomes, reducing wastage, and enhancing safety for patients. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: the distribution agreement with Dolfin may not achieve the anticipated benefits; market adoption may be slower than expected; the Company may face challenges in executing its pivot from B2C to B2B channels; regulatory or competitive challenges in new markets; adverse market conditions; changes in interest and currency exchange rates; and other factors beyond the control of the Company. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

*Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*

---

[1] <https://diabetesatlas.org/data-by-location/country/trkiye/>



To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/276623>